Illumina, Inc.

NASDAQ:ILMN

Medical - Diagnostics & Research

Healthcare
$210.01 +1.23%

+$1.95 today

Market cap
$31.75B
Beta
1.49
P/E (TTM)
28.9
EPS (TTM)
$5.58
52W Low $88.00High $177.22

Volume 1.63M

Average 1.65M

ILMN EBITDA Margin

EBITDA as a percentage of revenue.

Illumina, Inc.NASDAQ: ILMN

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 28.5%

EBITDA Margin was 28.5% in Q2 FY2026, down 9.3 pp from a year earlier. On a trailing-twelve-month basis it was 30.3%, down 11.3 pp year over year. Over 3 fiscal years it widened by 119.0 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 14 analysts of 27.0% for the fiscal year ending Dec 2026, down from 33.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
28.5%+5.6 pp QoQ
Last fiscal yearDec 2025
33.6%+50.2 pp YoY
LTMJun 2026
30.3%-11.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-9.3 pp-3.1 pp+6.1 pp
1 year+50.2 pp-6.6 pp-56.7 pp
3 years+119.0 pp-5.1 pp-124.1 pp
5 years-3.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
33.6%
Year-over-year change
+50.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ILMN compares with its peers on the latest reported figures

  • ILMN's LTM Jun 2026 EBITDA Margin of 30.3% is the highest of the 11 companies compared; the peer median is -25.7%.
  • Its year-over-year change of -11.3 pp is the 8th highest of 11, against a peer median of +4.4 pp.
  • Over three fiscal years its change of +119.0 pp compares with a peer median of +70.8 pp.
ILMN Competitors Peer median
EBITDA Margin for ILMN and competitors
Company Period LTM level YoY 3-year change
ILMNIllumina, Inc.LTM Jun 202630.3% -11.3 pp+119.0 pp
BLLNBillionToOne, Inc.LTM Jun 202612.6% +21.8 pp—
TXG10x Genomics, Inc.LTM Sep 20266.1% +10.9 pp+25.5 pp
NEONeoGenomics, Inc.LTM Jun 20261.7% +5.8 pp+10.8 pp
NTRANatera, Inc.LTM Jun 2026-6.6% +4.2 pp+53.9 pp
WGSGeneDx Holdings Corp.LTM Jun 2026-16.8% -24.5 pp+171.2 pp
GHGuardant Health, Inc.LTM Sep 2026-34.5% +4.7 pp+98.7 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-40.3% -32.6 pp-27.6 pp
PACBPacific Biosciences of California, Inc.LTM Mar 2026-66.6% +85.7 pp+198.6 pp
SOPHSOPHiA GENETICS S.A.LTM Mar 2026-81.4% -6.3 pp+87.8 pp
PSNLPersonalis, Inc.LTM Mar 2026-132.6% -47.0 pp—
Peer median (excluding ILMN) -25.7%+4.4 pp+70.8 pp

Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.53B4.58B4.5B4.37B4.34B
Cost of Revenue1.37B1.61B1.76B1.51B1.45B
Gross Profit3.15B2.97B2.74B2.86B2.89B
Gross Margin69.7%64.8%60.9%65.4%66.7%
Research & Development1.19B1.32B1.35B1.17B951M
Selling, General & Admin2.09B1.3B1.61B1.09B1.08B
Operating Expenses3.28B7.15B3.81B3.69B2.03B
Depreciation & Amortization251M394M432M354M270M
EBITDA1.2B(3.92B)(608M)(725M)1.46B
EBITDA Margin26.4%-85.4%-13.5%-16.6%33.6%
Operating Income(123M)(4.18B)(1.07B)(833M)864M
Operating Margin-2.7%-91.2%-23.7%-19.1%19.9%
Interest Income011M58M46M40M
Interest Expense61M26M77M100M101M
Other Income / Expenses1.01B(157M)(48M)(346M)222M
Income Before Tax884M(4.34B)(1.12B)(1.18B)1.09B
Pre-Tax Margin19.5%-94.6%-24.8%-27.0%25.0%
Income Tax Expense122M68M44M44M236M
Net Income762M(4.4B)(1.16B)(1.22B)850M
Net Margin16.8%-96.1%-25.8%-28.0%19.6%
EPS (Basic)5.08(28.05)(7.35)(7.69)5.48
EPS (Diluted)5.05(28.05)(7.35)(7.69)5.45
Weighted Avg Shares150M157M158M159M155M
Weighted Avg Shares (Diluted)151M157M158M159M156M

Illumina, Inc.

NASDAQ:ILMN

Intrinsic Alpha fair value

Locked

Current Price

$210.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.